Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01671319 · ClinicalTrials.gov registry record · Phase 2
Dose Dense TC + Pegfilgrastim Support for Breast Cancer
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT01671319 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 42 participants.
The verdict
NCT01671319, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the feasibility of giving standard TC chemotherapy on a dose dense schedule (ddTC) as well as evaluating the nature and frequency of ddTC side effects.
Interventions
- DRUG docetaxel + cyclophosphamide + pegfilgrastim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2011-06 |
| Est. Completion | 2013-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01671319
The ClinicalTrials.gov registry entry for NCT01671319 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which docetaxel + cyclophosphamide + pegfilgrastim is the first listed.
NCT01671319 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01671319 about?
NCT01671319 is a clinical study titled "Dose Dense TC + Pegfilgrastim Support for Breast Cancer". The purpose of this study is to determine the feasibility of giving standard TC chemotherapy on a dose dense schedule (ddTC) as well as evaluating the nature and frequency of ddTC side effects.
What is the current status of trial NCT01671319?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2011-06. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01671319?
The interventions under investigation include: docetaxel + cyclophosphamide + pegfilgrastim (DRUG).
Who is sponsoring clinical trial NCT01671319?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.